Fierce Pharma

DECEMBER 8, 2023

Alongside a historic approval for the first therapy utilizing the Nobel Prize-winning CRISPR/Cas9 gene-editing technology, the FDA has cleared a rival gene replacement therapy, also for sickle cell | Alongside a historic approval for the first therapy utilizing the Nobel Prize-winning CRISPR/Cas9 gene-editing technology, the FDA has cleared a rival gene replacement therapy, also for sickle cell disease (SCD).

FDA 328

FDA 328

MedCity News

DECEMBER 8, 2023

This week, two bipartisan members of the Senate Budget Committee launched an investigation into private equity and its impact on healthcare. They initiated the probe to get answers about “questionable financial transactions” that could be hurting care quality for patients at hospitals owned by private equity firms.

Healthcare 119

Healthcare Healthcare Patients Prospecting 119

Fierce Pharma

DECEMBER 8, 2023

Groundbreaking? Game-changing? Transformational? Historic? | Vertex Pharmaceuticals and CRISPR Therapeutics have won an historic FDA approval for their sickle cell disease gene therapy Casgevy. The transformational treatment is a potential cure for the debilitating and life-threatening disease which affects more than 100,000 in the United States, most of them Black.

FDA 312

FDA Medicine Pharmaceutical 312

MedCity News

DECEMBER 8, 2023

Looking back 20 years, when fewer than 18% of physician practices used electronic health records, few experts would have anticipated how information technology has changed healthcare. Thanks to IT, the volume and types of data generated and the speed at which they can be analyzed are vastly different than decades ago.

Healthcare 115

Healthcare Healthcare Electronics Physicians 115

Advertisement

Distribution

Fierce Pharma

DECEMBER 8, 2023

Three years on, Bristol Myers Squibb is bidding adieu to its top dealmaker. | Three years on, Bristol Myers Squibb is bidding adieu to its top dealmaker. Elizabeth Mily, who replaced BMS’ former M&A czar Paul Biondi back in 2020, is headed for the exit, the company confirmed Friday.

291

291

MedCity News

DECEMBER 8, 2023

Prescriptions for GLP-1s are soaring, but fewer than a third of people prescribed the costly drugs will continue taking them one year later without personalized support. Without the expert guidance of a registered dietitian, you risk not achieving the significant clinical benefits these drugs offer and forfeiting the potential for sustainable, transformative health outcomes.

Prescription 113

Prescription Biopharma 113

MedCity News

DECEMBER 8, 2023

To help keep participants engaged, and on trial, payment and reimbursement systems should offer the same level of flexibility that people have come to expect in every other walk of life.

Biopharma 110

Biopharma 110

PharmExec

DECEMBER 8, 2023

FDA approval of bluebird bio’s Lyfgenia and Vertex Pharmaceuticals' and CRISPR Therapeutics’ Casgevy marks significant milestone in the treatment of sickle cell disease.

FDA 115

FDA Pharmaceutical 115

MedCity News

DECEMBER 8, 2023

The first gene therapies for sickle cell disease are now approved: Casgevy from Vertex Pharmaceuticals Casgevy and Lyfgenia from Bluebird Bio. Despite the same-day approval, key differences give one of these therapies commercialization advantages over the other.

FDA 105

FDA Pharmaceutical Biopharma Pharma 105

PharmaTech

DECEMBER 8, 2023

This collaboration will combine BigHat Biosciences’ AI/ML-guided Milliner platform with AbbVie's expertise in oncology and neuroscience to develop next-generation antibodies.

97

97

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

European Pharmaceutical Review

DECEMBER 8, 2023

AbbVie has signed a definitive agreement to acquire Cerevel Therapeutics and its neuroscience pipeline – including antipsychotic emraclidine – for approximately $8.7 billion. Cerevel’s pipeline includes multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson’s disease, and mood disorders.

Safety 94

Safety FDA Management Pharmaceutical 94

PharmaTimes

DECEMBER 8, 2023

One-third of patients who received Pfizer’s COVID-19 vaccine had unintended immune responses - News - PharmaTimes

Patients 105

Patients 105

European Pharmaceutical Review

DECEMBER 8, 2023

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorised diabetes medicine, Mounjaro (tirzepatide), for weight loss and weight management in adults aged 18 and over. Mounjaro is now authorised for adults with a BMI of 30kg/m² or more (obesity), as well as those with a BMI between 27-30kg/m² (overweight) who also have weight-related health problems eg, prediabetes, high blood pressure, high cholesterol, or heart problems.

Management 87

Management Medicine Food Healthcare 87

Copyright Clearance Center

DECEMBER 8, 2023

AAP responded to tech industry assertions that respect for copyright is an obstacle to their innovation by labeling that as, “nonsense.

98

98

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Distribution

MedCity News

DECEMBER 8, 2023

As healthcare IT undergoes continual evolution, the integration of automation and human connection is poised to define the trajectory of IT support. This synergy promises a smooth experience for users and ultimately contributes to enhanced patient care.

Healthcare 80

Healthcare Healthcare Patients 80

Pharmaceutical Technology

DECEMBER 8, 2023

Pfizer has added the EU to its growing number of markets for its targeted immunotherapy intended for relapsed/refractory multiple myeloma.

Marketing 96

Marketing 96

Pharmaceutical Commerce

DECEMBER 8, 2023

Study analyzes and predicts how conditions in research and development can be predicted via computer simulation.

Pharmaceutical 104

Pharmaceutical 104

Pharmaceutical Technology

DECEMBER 8, 2023

The newly announced plans would allow third parties to manufacture such drugs if manufacturers make them unaffordable.

Manufacturing 98

Manufacturing 98

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Safety

PharmaTimes

DECEMBER 8, 2023

The project will explore the biology of human autoreactive plasma cells - News - PharmaTimes

98

98

MedCity News

DECEMBER 8, 2023

Check out news from FreezeNit, Vascular Perfusion Solutions, Kandu, and BetterYou.

Healthcare 101

Healthcare Healthcare 101

pharmaphorum

DECEMBER 8, 2023

The US FDA has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.

FDA 75

FDA Pharmaceutical 75

Referral MD

DECEMBER 8, 2023

Discover the best practices to enhance, improve, and boost patient referrals for your dermatology clinic. Understanding the Importance of Patient Referrals Patient referrals play a crucial role in the success of dermatology clinics. When patients refer someone to your clinic, they are satisfied with your services. Referrals also help to build trust and credibility for your clinic, as people are more likely to trust the recommendation of a friend or family member.

Patients 52

Patients Physicians Media Education 52

Advertisement

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

Specialization

pharmaphorum

DECEMBER 8, 2023

PharmStars digital health accelerator names fall 2023 grads Phil.

98

98

Pharmaceutical Commerce

DECEMBER 8, 2023

FDA approves bluebird bio’s Lyfgenia and Vertex Pharmaceuticals' and CRISPR Therapeutics’ Casgevy for the treatment of sickle cell disease, which affects approximately 100,000 people in the United States.

FDA 52

FDA Pharmaceutical 52

pharmaphorum

DECEMBER 8, 2023

Africa-led HIV vaccine trial ends in failure Phil.

98

98

PharmaTech

DECEMBER 8, 2023

AbbVie’s proposed acquisition of ImmunoGen is expected to accelerate AbbVie's entry into the commercial market for ovarian cancer and includes ImmunoGen’s flagship cancer therapy, ELAHERE (mirvetuximab soravtansine-gynx).

Marketing 52

Marketing 52

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Leads

Pharmaceutical Technology

DECEMBER 8, 2023

The combination therapy of Keytruda and Lenvima failed to meet the dual primary endpoints in a Phase III advanced endometrial cancer trial.

59

59

PharmaTech

DECEMBER 8, 2023

MilliporeSigma’s new platform combines generative AI, machine learning, and computer-aided drug-design aimed at increasing the success rate of new drugs and therapies.

52

52

Pharmaceutical Technology

DECEMBER 8, 2023

The US FDA has accepted Alpha Cognition’s new drug application (NDA) for ALPHA-1062 to treat mild-to-moderate Alzheimer’s disease.

FDA 59

FDA 59

Pharmacy Times

DECEMBER 8, 2023

Psychological safety substantially contributes to team effectiveness, learning, employee retention, and—most critically—better decisions and better performance.

Safety 64

Safety 64

Advertisement

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

Management